Stress Response in Opioid Use Disorder
Behavioral Strategies to Reduce Stress Reactivity in Opioid Use Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: R. Kathryn McHugh, PhD
- Phone Number: 617-855-3169
- Email: kmchugh@mclean.harvard.edu
Study Locations
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478
- Mclean Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years or older
- primary diagnosis of opioid use disorder
- ability to read and provide informed consent
Exclusion Criteria:
- major psychiatric or medical condition that would interfere with the ability to complete study procedures
- current opioid withdrawal
- presence of another current substance use disorder at a severity requiring acute treatment
- endocrine disease or current steroid prescription
- opioid-positive urine drug screen or breath alcohol test on the data or enrollment (not including prescribed medications)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Psychoeducational Control
|
The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
|
|
Experimental: Affect Regulation Condition
|
In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).
|
|
Experimental: Affect Labelling Condition
|
In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Negative Affect
Time Frame: Change measured over 2 time points during this 1-session study experiment (from start of a stress induction task to completion; approximately 10-15 minutes).
|
Negative affect will be measured using the Negative Affect Subscale of the Positive and Negative Affect Schedule.
This is a 10-item self-report measure on which respondents rate how strongly they are experiencing negative emotion.
The range of scores is 10-50, with higher scores representing higher negative affect.
|
Change measured over 2 time points during this 1-session study experiment (from start of a stress induction task to completion; approximately 10-15 minutes).
|
|
Distress Tolerance
Time Frame: Time-to-event outcome; during this 1-session study, this will measure time to outcome (discontinuation of task) from time of initiation of the stress induction task up to a maximum of 15 minutes later.
|
Distress tolerance will be measured using the Computerized Mirror Tracing Persistence Task.
This is a computer-based task in which participants trace a mirror on the screen using the cursor.
Participants are asked to persist at the task for as long as possible.
Time to discontinuation is used as a measure of distress tolerance (in seconds).
Longer duration reflects better tolerance of distress.
|
Time-to-event outcome; during this 1-session study, this will measure time to outcome (discontinuation of task) from time of initiation of the stress induction task up to a maximum of 15 minutes later.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Skin Conductance Level
Time Frame: Change measured over 2 time points during this 1-session study (prior to and during the stress induction task; approximately 10-15 minutes).
|
Skin conductance level is a physiological outcome that will be measured using electrodes placed on participants fingers, connected to a Biopac MP150 system with an ECG amplifier.
Change will be measures by subtracting the maximum value during the stress task from the value at the end of a baseline recording.
|
Change measured over 2 time points during this 1-session study (prior to and during the stress induction task; approximately 10-15 minutes).
|
|
Change in Cortisol Response
Time Frame: Change measured over 2 time points during this 1-session study (from start of stress induction task to 30 minutes after completion; approximately 40-45 minutes).
|
Cortisol levels will be measured using saliva samples.
Salivary cortisol levels are measured on a continuous scale (micrograms/deciliter).
|
Change measured over 2 time points during this 1-session study (from start of stress induction task to 30 minutes after completion; approximately 40-45 minutes).
|
|
Change in Opioid Craving
Time Frame: Change measured over 2 time points during this 1-session study (immediately prior to and at the completion of the stress induction task; approximately 10-15 minutes).
|
Self-report of opioid craving will be measured using the Opioid Craving Scale, a 3-item measure, with a range of 0-30, with higher scores representing strong opioid craving.
|
Change measured over 2 time points during this 1-session study (immediately prior to and at the completion of the stress induction task; approximately 10-15 minutes).
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2018P001419
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.